Compare Stocks: SKYE, BRNS, LTRN, and BYSI

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BRNS Barinthus Biotherapeutics	$0.76 +5.5%	$0.63	$0.51 ▼ $1.83	$31M	-0.37	65,709 shs	226,788 shs
BYSI BeyondSpring	$0.62 -0.7%	$1.09	$0.57 ▼ $2.44	$25.42M	0.06	2.07 million shs	26,911 shs
LTRN Lantern Pharma	$1.91 +1.9%	$2.81	$1.11 ▼ $4.70	$24.35M	2.3	137,983 shs	134,531 shs
SKYE Skye Bioscience	$1.86 +4.5%	$4.12	$1.64 ▼ $39.92	$8.24M	2.9	184,916 shs	182,857 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BRNS Barinthus Biotherapeutics	0.00%	+1.70%	+31.54%	+16.39%	-40.24%
BYSI BeyondSpring	0.00%	-7.11%	-28.95%	-63.85%	-66.04%
LTRN Lantern Pharma	0.00%	-7.97%	-31.47%	-46.94%	-55.59%
SKYE Skye Bioscience	0.00%	+4.79%	-50.71%	-68.29%	-93.08%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BRNS Barinthus Biotherapeutics	$0.76 +5.5%	$0.63	$0.51 ▼ $1.83	$31M	-0.37	65,709 shs	226,788 shs
BYSI BeyondSpring	$0.62 -0.7%	$1.09	$0.57 ▼ $2.44	$25.42M	0.06	2.07 million shs	26,911 shs
LTRN Lantern Pharma	$1.91 +1.9%	$2.81	$1.11 ▼ $4.70	$24.35M	2.3	137,983 shs	134,531 shs
SKYE Skye Bioscience	$1.86 +4.5%	$4.12	$1.64 ▼ $39.92	$8.24M	2.9	184,916 shs	182,857 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BRNS Barinthus Biotherapeutics	0.00%	+1.70%	+31.54%	+16.39%	-40.24%
BYSI BeyondSpring	0.00%	-7.11%	-28.95%	-63.85%	-66.04%
LTRN Lantern Pharma	0.00%	-7.97%	-31.47%	-46.94%	-55.59%
SKYE Skye Bioscience	0.00%	+4.79%	-50.71%	-68.29%	-93.08%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BRNS Barinthus Biotherapeutics	2.00	Hold	$4.00	427.01% Upside
BYSI BeyondSpring	1.00	Sell	N/A	N/A
LTRN Lantern Pharma	1.00	Sell	N/A	N/A
SKYE Skye Bioscience	2.20	Hold	$64.00	3,340.86% Upside

Current Analyst Ratings Breakdown

Latest SKYE, BRNS, LTRN, and BYSI Analyst Ratings

Date	Company	Brokerage	Action	Rating
9/3/2026	BYSI BeyondSpring	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/27/2026	SKYE Skye Bioscience	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/26/2026	BRNS Barinthus Biotherapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
8/25/2026	BRNS Barinthus Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/11/2026	BRNS Barinthus Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/29/2026	LTRN Lantern Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/21/2026	BRNS Barinthus Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/14/2026	LTRN Lantern Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/10/2026	SKYE Skye Bioscience	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/8/2026	BYSI BeyondSpring	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/29/2026	LTRN Lantern Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 9/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BRNS Barinthus Biotherapeutics	$14.97M	2.07	N/A	N/A	$1.40 per share	0.54
BYSI BeyondSpring	$1.75M	14.52	$0.11 per share	5.44	($0.88) per share	-0.70
LTRN Lantern Pharma	N/A	N/A	N/A	N/A	($0.25) per share	N/A
SKYE Skye Bioscience	N/A	N/A	N/A	N/A	($0.11) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BRNS Barinthus Biotherapeutics	-$66.43M	-$1.03	N/A	N/A	N/A	N/A	-59.15%	-43.80%	11/6/2026 (Estimated)
BYSI BeyondSpring	-$1.01M	-$0.12	N/A	N/A	N/A	N/A	N/A	-28.88%	11/12/2026 (Estimated)
LTRN Lantern Pharma	-$17.12M	-$1.62	N/A	N/A	N/A	N/A	-368.02%	-148.62%	11/11/2026 (Estimated)
SKYE Skye Bioscience	-$55.92M	-$10.16	N/A	N/A	N/A	N/A	-329.08%	-201.79%	N/A

Latest SKYE, BRNS, LTRN, and BYSI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	BYSI BeyondSpring	-$0.54	-$0.02	+$0.52	-$0.02	$8.77 million	N/A
8/14/2026	Q2 2026	LTRN Lantern Pharma	-$0.38	-$0.57	-$0.19	-$0.57	N/A	N/A
8/14/2026	Q2 2026	SKYE Skye Bioscience	-$0.29	-$0.27	+$0.02	-$2.4550	N/A	N/A
8/7/2026	Q2 2026	BRNS Barinthus Biotherapeutics	-$0.28	-$0.26	+$0.02	-$0.26	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BRNS Barinthus Biotherapeutics	N/A	N/A	N/A	N/A	N/A
BYSI BeyondSpring	N/A	N/A	N/A	N/A	N/A
LTRN Lantern Pharma	N/A	N/A	N/A	N/A	N/A
SKYE Skye Bioscience	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BRNS Barinthus Biotherapeutics	N/A	5.54	5.54
BYSI BeyondSpring	N/A	0.70	0.70
LTRN Lantern Pharma	N/A	1.96	1.96
SKYE Skye Bioscience	N/A	0.95	0.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BRNS Barinthus Biotherapeutics	25.20%
BYSI BeyondSpring	40.29%
LTRN Lantern Pharma	28.62%
SKYE Skye Bioscience	21.09%

Insider Ownership

Company	Insider Ownership
BRNS Barinthus Biotherapeutics	8.50%
BYSI BeyondSpring	29.31%
LTRN Lantern Pharma	8.50%
SKYE Skye Bioscience	6.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BRNS Barinthus Biotherapeutics	107	40.85 million	37.38 million	N/A
BYSI BeyondSpring	80	41.12 million	29.07 million	Optionable
LTRN Lantern Pharma	20	12.78 million	11.70 million	Optionable
SKYE Skye Bioscience	11	4.43 million	4.15 million	Optionable

SKYE, BRNS, LTRN, and BYSI Headlines

Recent News About These Companies

Skye Bioscience (SKYE) shares rise 6% after hours: Here's what's driving the move

August 26, 2026 | msn.com

Skye Bioscience (NASDAQ:SKYE) Director Sells 68,140 Shares

August 21, 2026 | insidertrades.com

Skye Bioscience, Inc. (SKYE) M&A Call Prepared Remarks Transcript

August 14, 2026 | seekingalpha.com

Skye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in Financings

August 14, 2026 | globenewswire.com

Pomerantz LLP Commences Class Action Against Skye Bioscience, Inc. – SKYE

July 12, 2026 | natlawreview.comN

Cadrenal Therapeutics Names Sharp Interim CFO

June 29, 2026 | marketwatch.com

Skye Bioscience Expands Authorized Shares After Shareholder Approval

May 29, 2026 | tipranks.com

Skye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1

May 20, 2026 | globenewswire.com

Skye Bioscience (SKYE) price target decreased by 11.48% to 7.87

May 14, 2026 | msn.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Coherus Biosciences (CHRS), Moderna (MRNA) and Skye Bioscience (SKYE)

May 14, 2026 | theglobeandmail.com

Skye Bioscience, Inc.: Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update

May 14, 2026 | finanznachrichten.de

Pomerantz LLP Files Investor Lawsuit Against Skye Bioscience, Inc. – SKYE

May 13, 2026 | natlawreview.comN

Skye Bioscience Initiates CBeyond™ Expansion Study (Part C) with Planned Review on May 18, 2026

May 12, 2026 | quiverquant.comQ

UPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update

May 12, 2026 | globenewswire.com

Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update

May 11, 2026 | globenewswire.com

Kuehn Law Encourages Investors of Skye Bioscience, Inc. to Contact Law Firm

April 22, 2026 | globenewswire.com

Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit

April 7, 2026 | globenewswire.com

Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development

April 2, 2026 | globenewswire.com

Skye Bioscience Inc (SKYE) Q4 2025 Earnings Call Highlights: Pioneering Advances in Obesity ...

March 11, 2026 | finance.yahoo.com

Skye Bioscience, Inc.: Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

March 11, 2026 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

SKYE, BRNS, LTRN, and BYSI Company Descriptions

Barinthus Biotherapeutics NASDAQ:BRNS

$0.76 +0.04 (+5.50%)

As of 09/4/2026 04:00 PM Eastern

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.

BeyondSpring NASDAQ:BYSI

$0.62 0.00 (-0.66%)

As of 09/4/2026 04:00 PM Eastern

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.

Lantern Pharma NASDAQ:LTRN

$1.90 +0.04 (+1.87%)

As of 09/4/2026 04:00 PM Eastern

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and pediatric rare disease designation. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Further, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. Lantern Pharma Inc. has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications. The company was incorporated in 2013 and is headquartered in Dallas, Texas.

Skye Bioscience NASDAQ:SKYE

$1.86 +0.08 (+4.49%)

As of 09/4/2026 04:00 PM Eastern

Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SKYE, BRNS, LTRN, and BYSI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SKYE, BRNS, LTRN, and BYSI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SKYE, BRNS, LTRN, and BYSI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SKYE, BRNS, LTRN, and BYSI Company Descriptions

Barinthus Biotherapeutics NASDAQ:BRNS

BeyondSpring NASDAQ:BYSI

Lantern Pharma NASDAQ:LTRN

Skye Bioscience NASDAQ:SKYE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SKYE, BRNS, LTRN, and BYSI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SKYE, BRNS, LTRN, and BYSI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SKYE, BRNS, LTRN, and BYSI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SKYE, BRNS, LTRN, and BYSI Company Descriptions

Barinthus Biotherapeutics NASDAQ:BRNS

BeyondSpring NASDAQ:BYSI

Lantern Pharma NASDAQ:LTRN

Skye Bioscience NASDAQ:SKYE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools